title: Clinical and immunologic follow-up study of patients with neurocysticercosis after treatment with praziquantel.
abstract: In a prospective study, 17 Brazilian patients with parenchymatous neurocysticercosis were monitored for a period of 12 months after treatment with praziquantel. Taenia solium-specific IgG antibodies, interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha, neopterin, and soluble interleukin-2 receptor (sIL-2R) were measured in serum and CSF before starting the therapy, on the last day of treatment, 5 weeks after treatment, and 3, 6, and 12 months after treatment. The most common symptoms and signs found in patients before treatment were headache, neck stiffness, and seizures. Six months after commencement of therapy, 13 of the 17 patients were free of complaints. Clinical normalization was paralleled by a significant decrease (p < 0.05) in the amount of intrathecally produced anti-T solium IgG 1 year after treatment. IL-1 beta was undetectable in serum at all times, whereas in the CSF it was within the normal range during the whole study period. The mean concentration of sIL-2R in the CSF was 65 kU/l (normal, < 50 kU/l) 5 weeks after treatment, whereas in all subsequent investigations sIL-2R was undetectable. The median CSF neopterin level was slightly elevated before treatment (6.8 nmol/l). One year after treatment, it had dropped by 69% (p < 0.001) to a median value of 2.1 nmol/l. The size of planimetrically measured focal cystic brain lesions on CT correlated with the amount of intrathecally synthesized anti-T solium IgG at the end of the study (r = 0.89, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Neurochemical Research Laboratory, Klinikum Steglitz, Free University of Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Rolfs
authors.forename: F
authors.initials: F
authors.lastname: Mühlschlegel
authors.forename: R
authors.initials: R
authors.lastname: Jansen-Rosseck
authors.forename: A R
authors.initials: AR
authors.lastname: Martins
authors.forename: E A
authors.initials: EA
authors.lastname: Bedaque
authors.forename: W M
authors.initials: WM
authors.lastname: Tamburus
authors.forename: L
authors.initials: L
authors.lastname: Pedretti
authors.forename: G
authors.initials: G
authors.lastname: Schulte
authors.forename: H
authors.initials: H
authors.lastname: Feldmeier
authors.forename: P
authors.initials: P
authors.lastname: Kremsner
mesh_terms: D000293:Adolescent; D000328:Adult; D000909:Antibodies, Helminth / Q000097:blood / Q000134:cerebrospinal fluid; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood / Q000134:cerebrospinal fluid; D001927:Brain Diseases / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D003551:Cysticercosis / Q000188:drug therapy* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000134:cerebrospinal fluid; D007375:Interleukin-1 / Q000097:blood / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D011223:Praziquantel / Q000627:therapeutic use*; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000032:analysis
chemical_list: D000909:Antibodies, Helminth; D007074:Immunoglobulin G; D007375:Interleukin-1; D015375:Receptors, Interleukin-2; D001708:Biopterins; D011223:Praziquantel; D019798:Neopterin